---
document_datetime: 2023-09-21 19:16:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/lucentis-epar-procedural-steps-taken-authorisation_en.pdf
document_name: lucentis-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3965198
conversion_datetime: 2025-12-30 02:05:50.16025
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Novartis  Europharm  Limited  submitted  on  8  February  2006  an  application  for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Lucentis,  through  the centralised  procedure  falling  within  the  Article  3(1)  and  point  1  of  Annex  of  Regulation  (EC)  No 726/2004.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83, as amended - complete and independent application

The application submitted is a complete dossier: composed of administrative information, complete quality  data,  non-clinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or bibliographic literature substituting/supporting certain tests or studies.

## Scientific Advice:

The  applicant  received  Scientific  Advice  from  the  CHMP  on  21  November  2003.  The  Scientific Advice pertained to clinical aspects of the dossier.

## Licensing status:

A new application was filed in the following country: USA.

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Bengt Ljungberg

Co-Rapporteur: Gonzalo Calvo Rojas

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 8 February 2006.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  18  May 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 23 May 2006.
- The procedure started on 1 March 2006.
- During  the  meeting  on  26-29  June  2006,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 29 June 2006.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 7 August 2006.
- The  summary  report  of  the  inspection  carried  out  at  the  following  site  Genentech,  Inc., 1 DNA Way, South San Francisco, CA 94080-4990, USA between 8 and 15 May 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 22 September 2006.
- During the CHMP meeting on 16-18 October 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 2 November 2006.
- During the meeting on 13-16 November, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Lucentis on 16 November 2006. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 15 November 2006.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 22 January 2007.